TWi Biotechnology, Inc

As of June 30, 2026, TWi Biotechnology, Inc carries a market capitalization of 5.47B, placing it among publicly traded companies globally. Its enterprise value stands at 5.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TWi Biotechnology, Inc has 207.58M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, TWi Biotechnology, Inc maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, TWi Biotechnology, Inc's stock has declined approximately 48.10% over the past 52 weeks. The 50-day moving average sits at 37.74, while the 200-day moving average is 27.12.

As of June 30, 2026, TWi Biotechnology, Inc holds 111.85M in cash and equivalents against 1.60M in total debt, resulting in a net debt position of -110.85M. Total book value stands at 477.35M, with working capital of 42.62M providing operational flexibility.

TWi Biotechnology, Inc's most recent stock split took place on July 13, 2026 with a 411:415 split ratio.